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1. Introduction 
1.1. Background 
1.1.1. Corticosteroids  
Corticosteroids are steroid hormones which are synthesized in the adrenal cortex and are 
involved in many physiologic processes, e.g. inflammatory reactions or the biochemical stress 
response. The synthesis of the corticosteroids is regulated by the hypothalamic-pituitary-axis: 
Different influences like stress, low blood levels of cortisol or illness lead to the secretion of 
the peptide corticotropin releasing hormone (CRH) from the hypothalamus. CRH triggers the 
anterior pituitary to release adrenocorticotropic hormone (ACTH). ACTH, in turn, stimulates 
the biosynthesis of corticosteroids in the adrenal gland. In a negative feedback mechanism, 
the synthesized corticosteroids affect the hypothalamus and anterior pituitary and inhibit the 
secretion of CRH and ACTH and thus, the synthesis of corticosteroids [1]. 
All corticosteroids are derived from cholesterol via various precursors through reactions of 
several enzymes [2, 3]. Depending on the involved enzymes and their localization in the 
adrenal cortex, there are three major pathways which lead to the three groups of 
corticosteroids: Glucocorticoids are synthesized in the zona fasciculata, mineralocorticoids in 
the zona glomerulosa and the synthesis of adrenal androgens takes place in the zona 
reticularis. The biosynthetic pathway of corticosteroids is schematically illustrated in 
Figure 1. 
Corticosteroids have various physiological functions: While mineralocorticoids, e.g. 
aldosterone, influence the electrolyte balance, androgens have an effect as sex hormones. 
Glucocorticoids, with the main representative cortisol, are important for the carbohydrate, 
lipid and protein metabolisms [1]. Latter also play an important role in stress situations, like 
severe infections, mental stress or surgeries. In such situations, the synthesis of CRH and 
ACTH is increased while simultaneously the cortisol plasma clearance is reduced. This leads 
to elevated cortisol concentrations, which are necessary to cope with the stress situation [4]. 
However, the significant effects of glucocorticoids during the stress response are up to now 
not yet completely understood [1]. However, their importance for the biochemical stress 
reaction becomes obvious in critical illness, where low cortisol levels are associated with 
poorer outcomes [5].   
Malfunction of the biosynthetic corticosteroid pathway leads to different endocrinological 
disorders whereby both overproduction and lack of corticosteroids have serious consequences. 
Some of these disorders can be traced back to a defect enzyme of the biosynthetic pathway. 
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The lack of the product or accumulation of the substrate of the respective enzyme can then be 
used for diagnosing purpose, e.g. elevated 17-OH-progesterone levels indicate congenital 
adrenal hyperplasia [6]. Thus, corticosteroids are important biomarkers for the functionality of 
the adrenal gland and reliable quantification methods are essential. However, corticosteroids 
are structurally closely related and therefore, accurate and selective quantification of these 
substances is challenging.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic biosynthetic pathway of corticosteroids.  
 
1.1.2. Liquid Chromatography - Tandem Mass Spectrometry (LC-MS/MS) 
There are different analytical measuring principles available for the quantification of 
corticosteroids and their precursors in human serum. In clinical routine laboratories they are 
usually quantified by immunoassays [7]. However, there are significant drawbacks of this 
technique such as cross reactivity with structurally related analytes, which can lead to 
ambiguous results as well as standardization issues between different laboratories, which can 
lead to substantial between-method bias [7, 8]. To overcome these problems, isotope dilution 
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liquid chromatography mass spectrometry is increasingly applied for quantification of steroid 
hormones [7, 9].  
Liquid chromatography is an analytical technique used to separate different compounds of a 
mixture of substances such as diagnostic serum samples. By pumping the mixture of analytes 
in a mobile phase through an analytical column, the compounds interact differently with the 
stationary phase of the column according to their chemical properties, mainly their polarity. 
Thus, the retention time of the analytes on the stationary column varies, which leads to 
separation of the compounds [10]. 
To detect the separated analytes, liquid chromatography is often coupled to mass 
spectrometry, which differentiates the analytes due to different mass-to-charge-ratios and 
determines their molecular mass and their fragmentation patterns. To this end, the analytes are 
transferred into the gas phase, ionized in the ion source, e.g. by electrospray ionization, and 
accelerated through an electrostatic field into the analyzer. There are different analyzers; the 
most widely used in clinical laboratories are triple quadrupoles. A quadrupole consists of four 
parallel metal rods, to which an AC and DC voltage is applied, forming an electrical 
quadrupole field when diagonally opposing rods are on the same neighboring rods on inverted 
electrical potential. Only ions with a selected mass-to-charge ratio can pass this quadrupole 
field along the metal rods, other ions are emitted laterally and discharged by collision with the 
rods (see Figure 2). 
 
 
 
 
 
 
 
 
Figure 2: Schematic structure of a quadrupole. Only ions with a determined mass-to-charge 
ratio have a stable flight pass and reach the detector (green line), other ions (blue line) are 
discharged.   
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A triple quadrupole system consists of two quadrupoles which are connected via a collision 
cell (which is also built as a quadrupole). This structure is often referred to as tandem mass 
spectrometry due to the multiple steps of mass spectrometric selection. For quantification, the 
multi-reaction monitoring is widely used as mode of action: In the first quadrupole, ions with 
a defined mass-to-charge-ratio are selected. In the following collision cell these ions, the so-
called precursors, are fragmented by collision with a collision gas (e.g. Nitrogen). The formed 
fragment ions, the so-called product ions, are highly specific for the analyte and they are 
transferred to the following quadrupole. Here, a determined ion fragment is selected and can 
pass to the detector, e.g. a photomultiplier [11] (see Figure 3).      
 
 
 
 
 
 
Figure 3: Schematic diagram of a triple quadrupole mass spectrometer operating in multi-
reaction monitoring. 
 
This technique enables an improved selectivity compared to immunoassays. Therefore, LC-
MS/MS is becoming the method of choice for steroid measurement in clinical laboratories [7, 
9, 12]. A further advantage of this technique is the possibility of simultaneous quantification 
of several analytes within one run [12] which is especially useful with regard to metabolic 
profiling, e.g. steroid profiling (see section 1.1.4.). Furthermore, LC-MS/MS methods can be 
developed independently, and thus, there is no dependence on industrial suppliers. Another 
essential aspect is the use of stable isotope-labelled internal standards in LC-MS/MS methods 
which is known as “isotope dilution” [13]. These internal standards have almost the same 
physical and chemical properties as the analytes but include an isotope labelling, e.g. the 
exchange of 12C atoms with 13C atoms or the replacement of hydrogen with deuterium. Due to 
the exchanged atoms the complete molecule has a different mass and can be discriminated in 
the mass spectrometer. At the beginning of the sample preparation, a known amount of those 
isotope-labelled substances is added to a determined sample volume which contains the 
respective analyte. For the quantification of the analyte, the area ratio of analyte area to 
internal standard area is used. Because the analyte and its isotope-labelled counterpart 
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undergo the same processing steps, the use of stable isotope-labelled internal standards 
corrects analyte losses due to the sample preparation. Furthermore, it compensates possible 
effects during ionization, e.g. ion suppression or ion enhancement, due to co-eluting 
components of the sample matrix [13-15], which is known as matrix effect. Because of 
different challenging matrices used in clinical laboratories, like serum, whole blood or urine, 
the isotope dilution approach is an important advantage of LC-MS/MS compared to other 
analytical approaches ensuring reliable and robust quantification. 
 
1.1.3. ACTH stimulation test 
Quantification of corticosteroids is an important task of clinical laboratories and there are 
diagnostic tests, e.g. the ACTH stimulation test, which rely on the measurement of at least one 
corticosteroid as read-out. The ACTH stimulation test assesses the functional capacity of the 
adrenal gland [16]. Therefore, 250 µg of synthetically produced peptide, which consists of 24 
amino acids (Tetracosactidhexaacetat), with a comparable biological efficacy to ACTH, is 
intravenously administered. Blood sampling is performed before and 30 or 60 minutes after 
the intravenous injection; as standard read-out, serum cortisol is determined. According to the 
physiological function of ACTH described in section 1.1.1, the concentration of cortisol in 
healthy individuals increases after injection of the ACTH analogue. A missing increase is an 
indication of malfunction of the adrenal gland and therefore, the test is used as diagnostic tool 
for adrenal insufficiency [16, 17].  
Furthermore, ACTH stimulation can also be used as a model for stress situations because it 
simulates maximum physiological stress. Thus it can be used for studying the biochemical 
stress response of the human body. By broadening the read-out to a set of steroids, a deeper 
insight to the physiological reactions to stress is possible. In this context, a profile of different 
steroids may be advantageous compared to solely measuring cortisol. 
 
1.1.4. Steroid profiling 
The quantification of several endogenous steroids at once is referred to as steroid profiling 
and allows for a deeper insight into the underlying biochemical processes of different 
disorders compared to measuring cortisol as single marker. Analogous to the more general 
metabolic profiling - the simultaneous assessment of various analytes related to a metabolic 
pathway [18] - steroid profiling is an increasingly widespread tool in clinical diagnostics 
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because of the gain of additional information. There are several clinical conditions in which 
measuring and monitoring steroid hormones and their corticoid precursors are meaningful. 
Steroid profiling is for example used to confirm congenital adrenal hyperplasia [19], in the 
diagnostic workup of adrenal dysfunction [20], and for differential diagnosis of adrenal 
tumors [21]. 
Besides its application in the diagnostic workup of different diseases, steroid profiling is also 
important in the field of clinical research. As mentioned in section 1.1.1., cortisol plays a 
crucial role in the biochemical stress response of the human body. However, the underlying 
processes of the stress reaction are up to now not yet completely understood. By measuring a 
panel of steroids instead of solely cortisol, a better understanding may be achieved.  
 
1.1.5. Aim and scope 
In this research project we aimed at utilizing the advantages of the LC-MS/MS technique for 
the measurement and quantification of corticosteroids. Because this technique overcomes the 
above-mentioned drawbacks of immunoassays, which are at present commonly used in 
routine laboratories for measuring corticosteroids, this can contribute to an improvement of 
diagnostic methods in clinical laboratories and thus to a better patient care. 
In the first part of the project the objective was to develop and evaluate a LC-MS/MS method 
for the reliable quantification of 12 corticosteroids. 
In the second part the clinical application of such a LC-MS/MS method was addressed. We 
obtained a corticosteroid profile of healthy individuals involved in an ACTH stimulation 
study by using a LC-MS/MS method. These data contribute to the establishment of normal 
ranges for corticosteroid concentrations in humans before and after ACTH stimulation.       
   
1.2. Development of a multi-analyte isotope dilution LC-MS/MS method for 
corticosteroid profiling 
As mentioned in section 1.1.1., diagnosing and monitoring of several endocrine disorders 
depend on the quantification of corticosteroids. Thus, the development of reliable and specific 
quantification methods for corticosteroids is important to provide meaningful information for 
the clinicians. Due to the above-mentioned advantages, LC-MS/MS is well suited for steroid 
analysis. Nevertheless, the method must be thoroughly established. Thereby, the major 
challenge of the method development is the sufficient chromatographic separation of isobars 
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which are substances with the same molecular mass and fragmentation pattern. These analytes 
cannot be differentiated in the mass spectrometer and chromatographic separation is therefore 
crucial for a reliable quantification of corticosteroids. 
Most of the existing LC-MS/MS methods for steroid quantification use stationary phases 
having C18 groups as surface modification. To improve the chromatographic separation, we 
investigated the suitability of a reversed phase column with biphenyl groups on the surface. 
An improved resolution of our targeted analytes was achieved using such a stationary phase 
compared to the standard modification of C18-groups. This is expected as a consequence of 
possible π-π interactions between the biphenyl rings of the stationary phase and the steroid 
molecules [9], additional to the common van-der-Waals interactions between lipophilic 
groups, which represent the main interaction with a C18 modification. Another important 
aspect in method development is the sample preparation, which should be preferably short 
und not elaborate. Nevertheless, it is essential to remove matrix components like 
phospholipids and proteins, which could interfere with the measurement and contaminate the 
instruments. Therefore, we performed a protein precipitation with zinc trifluoroacetate (TFA) 
in methanol as a novel precipitation agent. TFA is volatile and therefore contamination of the 
mass spectrometer can be minimized. A comparison between this precipitation agent and the 
long-established methanol zinc sulfate precipitation showed a comparable precipitation 
efficacy regarding protein content and phospholipid profile. Additionally, we applied 
ammoniumfluoride as a rarely used additive for the mobile phase to improve the sensitivity of 
the method. This aspect is important due to the low concentrations of some endogenous 
steroids.  
After the development, a method should be comprehensively validated to ensure that it 
provides reproducible, reliable results and to characterize the method performance. 
Unfortunately, widely accepted guidelines for method validations for methods assessing 
endogenous compounds are lacking. Thus, these assays are often validated according to the 
Guideline of bioanalytical method validation by the European Medicines Agency, which was 
actually established for methods addressing drug concentrations in biological matrices [22]. 
There are different method characteristics which should be addressed during validation. Very 
important is the assurance of specificity, in particular in the context of isobaric compounds. 
Accuracy and precision are also essential method characteristics which should be investigated 
during method validation. While precision is an indication of the consistency of repeated 
measurements and shows the spread of measuring points, accuracy describes the closeness of 
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the value measured by the method to the nominal value. The matrix effect is a further aspect 
which should be addressed during validation and reflects the potential influence of sample 
matrices on the measurement. Furthermore, the validation should describe carry-over, lower 
limit of quantification and stability [22]. 
These aspects were addressed in the first publication in which we could present a thoroughly 
developed and validated LC-MS/MS method for the quantification of 12 steroids which is 
suitable for steroid profiling.  
The author of this doctoral thesis was involved in all parts of the described publication: 
Planning of the project, experimental laboratory work for the LC and MS method 
development, preparation of the samples series for the method validation, performing the 
measurements, data analysis and writing the manuscript.     
   
1.3. Application of a multi-analyte isotope dilution LC-MS/MS method for 
corticosteroid profiling after ACTH administration in individuals without 
endocrine disorders  
Since steroid profiling is becoming a frequently used tool in endocrinology, normal 
corticosteroid concentration ranges for individuals without endocrine disorders are necessary 
for the correct assessment of values measured in patients’ samples. At the time of our 
investigation, there was already data available in literature for basal corticosteroid 
concentrations in healthy individuals, but there was only sparse comparative data available for 
corticosteroid concentrations after ACTH stimulation. Thus, the biochemical stress response 
to ACTH in healthy individuals regarding the respective corticosteroid concentrations has not 
been addressed sufficiently so far. 
Therefore, we performed an ACTH stimulation study with individuals who are not suspected 
to have endocrinological disorders. The concentrations of 6 corticosteroids (cortisol, 
cortisone, corticosterone, 11-deoxycorticosl, 17-OH-progesterone, and 11-deoxycortico-
sterone) were measured in the blood samples via a validated LC-MS/MS method before and 
after ACTH stimulation. 
With this work we contributed to the establishment of normal ranges of corticosteroids after 
intravenous injection of ACTH. These data are necessary to study differences in the human 
stress response depending on the physical condition. A characteristic pattern of changes in the 
concentrations of the measured corticosteroids was obtained. Our results particularly suggest 
further investigation of corticosterone as a sensitive new stress marker for stress research but 
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maybe also for diagnostic testing, because it showed a much more pronounced increase after 
ACTH administration than cortisol, the standard read-out of the test. A further aspect revealed 
in our study is the missing standardization in steroid measurement among different 
laboratories and methods. Thus, inter-laboratory method comparisons seem to be necessary to 
standardize results of corticosteroid measurements. 
To this publication, the doctoral candidate contributed by performing sample preparations and 
measurements of the study samples. Data analysis and writing of the manuscript are further 
contributions to this work.    
 
1.4. Summary / Zusammenfassung 
Corticosteroid profiling is becoming increasingly significant for diagnosing and 
differentiating various endocrinological disorders and for stress research. Therefore, reliable 
quantification methods for corticosteroids are mandatory. Due to the advantages of LC-
MS/MS methods like improved selectivity compared to immunoassays and the possibility of 
using isotope-labelled internal standards, this technique is very appropriate to use it for the 
diagnostic workup of patients’ samples.   
Therefore, a LC-MS/MS method for quantification of 12 corticosteroids was developed in the 
first part of this doctoral thesis. By using a biphenyl column as stationary phase, very good 
separation of the isobaric compounds was achieved. The validation of the developed method 
proofs the suitability for the targeted steroid profiling.  
In the second part, a profile of 6 corticosteroids of individuals not suspected to be suffering 
from endocrinological disorders was assessed before and after ACTH stimulation by using a 
LC-MS/MS method. The collected data can support the establishment of normal ranges of 
corticosteroid concentrations after ACTH stimulation and therefore contribute to the 
investigation of the biochemical stress response. Additionally, corticosterone was identified as 
potential new stress marker. 
 
Corticosteroid Profiling gewinnt zunehmend an Bedeutung in der Diagnose und 
Differenzierung verschiedener endokrinologischer Erkrankungen sowie in der 
Stressforschung. Voraussetzung dafür sind verlässliche Methoden zur Quantifizierung der 
einzelnen Corticosteroide. Aufgrund der Vorteile der LC-MS/MS Methoden, z.B. der 
verbesserten Selektivität gegenüber Immunoassays und der möglichen Verwendung von 
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isotop-markierten internen Standards, sind sie für die diagnostische Bewertung von 
Patientenproben gut geeignet. 
Im Rahmen dieser Doktorarbeit wurde im ersten Teilprojekt daher eine LC-MS/MS Methode 
zur Quantifizierung von 12 Corticosteroiden entwickelt. Durch die Verwendung einer 
Biphenylsäule als stationäre Phase konnte eine sehr gute Isobarentrennung erzielt werden. Die 
Validierung der entwickelten Methode zeigte, dass diese für die Erfassung von 
Steroidprofilen gut geeignet ist. 
Im zweiten Teilprojekt der Arbeit wurde mittels einer LC-MS/MS Methode ein 6 
Corticosteroide umfassendes Steroidprofil von Probanden ohne Verdacht auf 
endokrinologische Erkrankungen vor und nach ACTH Stimulation erfasst. Die erhobenen 
Daten können zur Erstellung von Normbereichen für Corticosteroidkonzentrationen nach 
ACTH Stimulation beitragen und stellen dadurch einen Beitrag zur Untersuchung der 
biochemischen Stressantwort dar. Zudem konnte Corticosteron als möglicher neuer, sensitiver 
Stressmarker identifiziert werden.  
10
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The  measurement  of steroid  hormones  and their  corticoid  precursors  is an  important  aspect  in
endocrinology  since  these  analytes  are  biomarkers  for  several  endocrine  disorders.  Over  the  last  few  years,
HPLC–MS/MS  has  become  the method  of  choice  to analyze  these  compounds.  There  are  already  several
methods  using  stationary  phases  modiﬁed  with  C18 groups.  However,  since  these  columns  sometimes
do  not  enable  sufﬁcient  separation  of some  isobaric  steroids,  we  investigated  the  potential  of  a  different
RP  modiﬁcation  using  biphenyl  groups  for  the  separation  of challenging  isobars  such  as  corticosterone,
11-  and 21-deoxycortisol.
The aim of our work  was the  development  of  an isotope  dilution  UHPLC–MS/MS  assay  for  clinical
research  that  combines  simple  and  effective  sample  preparation  with  a powerful  MS method  quan-
tifying  a broad  steroid  panel  (aldosterone,  corticosterone,  cortisol,  cortisone,  11-deoxycorticosterone,
11-deoxycortisol,  21-deoxycortisol,  dehydroepiandrosterone,  dehydroepiandrosterone  sulfate,  17-OH-
progesterone,  progesterone,  and  testosterone)  in human  serum.
After a manual  protein  precipitation  step  using  zinc  triﬂuoroacetate  (ZnTFA)  in methanol,  the super-
natants  were  directly  injected  into  the UHPLC–MS  system.  Chromatographic  baseline  separation  of all
isobaric  compounds  (corticosterone  ↔  11-deoxycortisol  ↔  21-deoxycortisol,  17-OH-progesterone  ↔  11-
deoxycorticosterone,  and  aldosterone  ↔  cortisone)  was  achieved  using  a Kinetex  Biphenyl  column
(150  × 2.1  mm,  1.7 m)  with  a mobile  phase  consisting  of 0.2  mM  ammonium  ﬂuoride  in water  and
methanol.  The  total  run time  was  10 min.  For  detection  we  used  a Xevo  TQ-S  mass  spectrometer  oper-
ating  in  the  ESI  positive  and  negative  modes.  The  method  was  validated  according  to  the EMA  guideline
for  bioanalytical  method  validation.
The results  for  accuracy  (within-run:  92.3%–115%,  between-run:  92.4  %–113%)  and  imprecision
(within-run:  0.80%–9.05%,  between-run:  1.98  %–15.2%)  were  satisfying.  The  recovery  ranged  from  95%
2to  111%.  The  matrix  effect  was  between  93%  and  112%  and  an  excellent  linearity  with  R > 0.99  for  all
analytes  was achieved.
It was  demonstrated  that  biphenyl  based  columns  are  a powerful  tool  for comprehensive,  MS based
steroid  assays  including  various  isobaric  substances.  Additionally,  we  could  evince  that  ZnTFA  is  a  con-
venient  precipitation  agent  suitable  for steroid  analysis.
©  2017  Elsevier  B.V.  All  rights  reserved.. Introduction
Steroid hormones and their corticoid precursors are impor-
ant biomarkers to diagnose and monitor a broad spectrum of
ndocrine disorders such as Cushing’s disease, adrenal failure, pri-
ary hyperaldosteronism, or congenital adrenal hyperplasia [1–3].
he assessment of a broad steroid panel could contribute to a better
ifferentiation and understanding of these disorders [4–6]. Addi-
∗ Corresponding author.
E-mail address: johanna.lindner@med.uni-muenchen.de (J.M. Lindner).
ttp://dx.doi.org/10.1016/j.jpba.2017.04.020
731-7085/© 2017 Elsevier B.V. All rights reserved.tionally, cortisol and its precursors are involved in the human stress
response [7], therefore steroid proﬁling can contribute to a bet-
ter understanding of the underlying biochemical processes under
stress conditions. As a consequence, it may  allow insight into the
stress situation of the human body in critical situations such as
surgery and critical illness, especially since it was found that the
total serum cortisol level correlates with the severity of the illness
of critical ill patients [8].In clinical routine laboratories, steroid hormones are commonly
measured by immunoassays. Although this analytical technique
is well established and has been used for a long time, there are
some important drawbacks that can compromise the results. Cross
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eactivity with structurally related components or metabolites
s an issue as well as a poor agreement between commercially
vailable immunoassays and a lack of sensitivity [9–12]. Recently,
PLC–MS/MS assays addressing steroid hormones started to
eplace conventional immunoassays [13]. Due to its sensitivity
nd, more importantly its speciﬁcity, the HPLC–MS/MS tech-
ique is a highly attractive analytical method for differentiating
etween structurally very similar steroids that cannot be achieved
y immunoassays. Furthermore, it allows for the possibility of
nalyzing a broad panel of target analytes simultaneously. As a con-
equence, this technique is becoming the gold standard in the ﬁeld
f clinical research and routine diagnostics [11,13].
Even if mass spectrometry allows discrimination between
tructurally similar compounds, it cannot differentiate between
o-called isobaric substances, which have the same mass of the
ntact molecule but also of the respective fragments. Thus, the main
hallenge of steroid HPLC–MS/MS assays is the chromatographic
eparation of these isobaric compounds. So far, stationary phases
odiﬁed with C18 groups are the standard for steroid assays. How-
ver, separating isobaric compounds with these stationary phases
equires complex solvent gradients combined with long run times.
everse phase columns based on biphenylic groups seem to be a
romising tool for corticosteroid separation because of the forma-
ion of - interactions with the steroid molecules [13].
Therefore, we decided to develop and evaluate a clinical
esearch LC–MS/MS assay for a broad steroid panel that includes
everal isobaric compounds using a biphenyl column as the sta-
ionary phase. Simultaneous, reliable and sensitive quantiﬁcation
f 12 endogenous steroids in human serum should be combined
ith a simple and effective sample preparation method employing
 small sample volume.
.  Materials and methods
.1.  Chemicals and reagents
Methanol  and water were of UHPLC grade and purchased from
iosolve (Valkenswaard, The Netherlands). Standards for aldos-
erone, corticosterone, cortisone, cortisol, 11-deoxycorticosterone,
1-deoxycortisol, 17-OH-progesterone, progesterone, and testos-
erone; labelled internal standards for aldosterone-d7, DHEA-d6,
HEAS-d5, progesterone-d9, and testosterone-13C3; ammonium
uoride as mobile phase additive, and zinc triﬂuoroacetate
ZnTFA) as precipitating agent were purchased from Sigma-
ldrich (Steinheim, Germany). 21-Deoxycortisol, DHEA, DHEAS,
1-deoxycortisol-d8, and cortisol-d3, were obtained from Cam-
ridge Isotope Laboratories (Tewksbury, Massachusetts, USA) and
ortisone-d8, 11-deoxycorticosterone-d8, and 11-deoxycortisol-
7, were from Toronto Research Chemicals (Toronto, Canada).
orticosterone-d8 and 17-OH-progesterone-d8 were purchased
rom CDN Isotopes (Pointe-Claire, Canada).
Steroid stripped serum used for calibration and QC samples was
btained by unspeciﬁc depletion with charcoal.
.2. Calibrators, quality control samples (QC) and internal
tandard solution
Stock  solutions of the steroids and internal deuterated standards
ere prepared in methanol containing a nominal concentration
f 100 g/mL. Aldosterone-d7 was dissolved in acetonitrile. Solu-
ions were stored at −80 ◦C. The respective steroids were combined
o obtain a methanolic master calibration solution. The calibra-
ors were prepared by serial dilution of this methanolic master
alibration solution with human steroid stripped serum. Three con-
entration levels of QCs based on human steroid stripped serumFig. 1. LC-gradient of the chromatographic method. Mobile phase A: 0.2 mM ammo-
nium ﬂuoride in water; mobile phase B: methanol.
were spiked at low, medium, and high concentrations within
the calibration range. Additionally, certiﬁed controls [GC–MS and
LC–MS reference measurement procedure speciﬁed proﬁciency
testing materials purchased by the reference institute for bioanalysis
(RfB Bonn, Germany)] [14–18] were used for aldosterone, cortisol,
DHEAS, 17-OH-progesterone, progesterone, and testosterone. The
exact concentrations of the master calibration solution, calibrators
and QCs are shown in Table 1 and Table 3.
The internal standard solution was prepared in methanol
by mixing the stock solutions of the deuterated standards to
the following concentrations: cortisol-d3 50 ng/mL; cortison-d8,
corticosterone-d8, 11-deoxycortisol-d7, and 21-deoxycortisol-
d7 10 ng/mL; 17-OH-progesterone-d8, 11-deoxycorticosterone-d8,
aldosterone-d7, progesterone-d9, and testosterone-d3 5 ng/mL;
DHEA-d6 70 ng/mL, and DHEAS-d5 200 ng/mL.
2.3. Sample preparation
The  precipitation agent was  prepared freshly every day by dilut-
ing the internal standard solution 1:100 with a methanolic 124 mM
ZnTFA solution. An aliquot of 50 L of the sample (or calibrator, QC,
blank) was mixed with 25 L precipitation agent. The samples were
vigorously mixed for 10 s and shaken for 10 min. A centrifugation
step followed (10 min, 15 ◦C, 15 000 rpm). The clear supernatants
were transferred to glass vials with micro inserts (Chromatographie
Handel Müller, Fridolﬁng, Germany) and placed into an autosam-
pler.
2.4. UHPLC and MS/MS conditions
For the analysis of the samples an Acquity UHPLC system, con-
sisting of an autosampler, a switching valve, a column oven, and
two pairs of pumps, coupled to a Xevo TQ-S was used (Waters,
Milford, Massachusetts, USA). For controlling the instruments, data
acquisition, and processing Mass Lynx V 4.1 software (Waters) was
used. Chromatographic separation was performed on a Kinetex
Biphenyl column (150 × 2.1 mm,  1.7 m;  Phenomenex, Torrance,
California, USA) equipped with a Security Guard ULTRA cartridge
(UHPLC Biphenyl, for 2.1 mm  ID columns, Phenomenex). The col-
umn  oven was kept at 50 ◦C, the injection volume was  set to 5 L.
Mobile phase A was  composed of 0.2 mM ammonium ﬂuoride in
H2O (pH ∼5.6); mobile phase B consisted of methanol. The gradi-
ent is shown in detail in Fig. 1. The ﬂow rate was set to 0.3 mL/min.
The total run time amounted to 10 min. In order to reduce contam-
ination of the mass spectrometer the ﬁrst 0.5 min  of the eluents
were sent to waste.The  parameters of the mass spectrometer were optimized as
follows: source temperature 150 ◦C, source gas ﬂow 150 L/h, desol-
vation temperature 500 ◦C, desolvation gas ﬂow 500 L/h, a capillary
voltage of 1.3 kV and a cone voltage of 30 V for positive electro-
13
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Table 1
Concentrations [ng/ml] of the master calibration mix  (MCM)  and the calibrators (Cal). ALDO: aldosterone, 17-OHP: 17-OH-progesterone, 21-DF: 21-deoxycortisol, B:
corticosterone, DHEA: dehydroepiandrosterone, DHEAS: dehydroepiandrosterone sulfate, DOC: 11-deoxycorticosterone, E: cortisone, F: cortisol, PG: progesterone, S:
11-deoxycortisol, T: testosterone.
Concen tration s printed in grey are outside the calibration rang e.  
ALDO  17-OHP  21-DF  B  DHEA  DHEAS  DOC  E  F  PG  S  T 
Range  0.25-48 .7  0.08-36 .9  0.19-93 .0  0.23-115  4.76-476 20 .1-5025  0.02-25 .1  1-250  1.08-538  0.05-24 .6  0.12-59 .2  0.02-25 .1 
MCM 243 923 465 575 4755 50250 251 2498 2692 246 592 251 
Cal 1 0.02 0.08 0.04 0.04 0.38 4.02 0.02 0.20 0.22 0.02 0.04 0.02 
Cal 2 0.05 0.18 0.09 0.11 0.95 10.05 0.05 0.50 0.54 0.05 0.12 0.05 
Cal 3  0.10  0.37  0.19  0.23  1.90 20 .1  0.10  1.00  1.08  0.10  0.24  0.10 
Cal 4 0.25 0.93 0.47 0.58 4.76 50.3 0.25 2.50 2.69 0.25 0.59 0.25 
Cal 5 0.97 3.69 1.86 2.30 19.0 201 1.00 9.99 10.8 0.98 2.37 1.00 
Cal 6 4.87 18.5 9.30 11.5 95.1 1005 5.02 50.0 53.8 4.92 11.8 5.02 
Cal 7 9.73 36.9 18.6 23.0 190 2010 10.1 99.9 108 9.83 23.7 10.03 
Cal 8 24.3 92.3 46.5 57.5 476 5025 25.1 250 269 24.6 59.2 25.1 
Cal 9 48 .7  185 93 .0  115  951  10050 50 .3  500  538 49 .2  118 50 .2 
Table 2
MS/MS  parameters for the targeted steroids and their internal standards.
Analyte Molecular
weight
[g/mol]
Corresponding
internal
standard
Retention
time  [min]
Precursor
ion [m/z]
Quantiﬁer
product ion
[m/z]
Quantiﬁer
CE  [eV]
Qualiﬁer
product ion
[m/z]
Qualiﬁer
CE  [eV]
Dwell
time [s]
Aldosteronea 360.19 Aldosterone-d7 3.30 361.0 343.0 16 0.012
Corticosteroneb 346.21 Corticosterone-d8 4.21 347.0 120.9 24 96.9 24 0.012
Cortisol 362.21 Cortisol-d3 2.47 363.1 120.9 20 309.2 18 0.020
Cortisonea 360.19 Cortisone-d8 2.74 361.0 163.1 24 121.0 28 0.012
11-Deoxycorticosteronec 330.21 11-Deoxycorticosterone-d8 5.85 331.1 96.9 22 109.0 26 0.049
11-Deoxycortisolb 346.21 11-Deoxycortisol-d7 3.86 347.1 96.9 26 109.0 26 0.012
21-Deoxycortisolb 346.21 21-Deoxycortisol-d8 2.91 346.9 120.9 26 311.1 14 0.012
DHEA 288.21 DHEA-d6 4.53 271.1 252.8 16 196.7 20 0.016
DHEAS 368.17 DHEAS-d5 1.68 367.2 96.9 −20 0.024
17-OH-Progesteronec 330.21 17-OH-Progesterone-d8 4.85 331.1 96.9  24 108.9 26 0.016
Progesterone 314.22 Progesterone-d9 7.33 315.1 108.9 24 96.9 24 0.055
Testosterone 288.21 Testosterone-d3 4.80 289.1 96.9 24 109.0 28 0.016
Aldosterone-d7 367.19 3.23 369.2 351.0 16 0.012
Corticosterone-d8 354.21 4.13 355.0 337.2 14 0.012
Cortisol-d3 365.21 2.46 366.0 120.9 22 0.020
Cortisone-d8 368.19 2.71 369.1  168.0 24 0.012
11-Deoxycorticosterone-d8 338.21 5.77 339.0 99.9 26 0.049
11-Deoxycortisol-d7 353.21 3.81 354.0 99.9 24 0.012
21-Deoxycortisol-d8 354.21 2.87 354.9 319.2 14 0.012
DHEA-d6 294.21 4.49 277.0 259.1 14 0.016
DHEAS-d5 373.17 1.68 372.1 97.8 −28 0.024
17-OH-Progesterone-d8 338.21 4.80 339.0 99.9 22 0.016
Progesterone-d 323.22 7.26 324.0  99.9 20 0.055
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Testosterone-13C3 291.21 4.78 
,b,cRespective isobaric compounds.
pray ionization (ESI + ), which was used for all analytes except for
HEAS. For this analyte, we used negative electrospray ionization
ESI-): source temperature 150 ◦C, source gas ﬂow 150 L/h, desolva-
ion temperature 500 ◦C, desolvation gas ﬂow 700 L/h, a capillary
oltage of 2.5 kV and a cone voltage of 40 V. For all analytes and
nternal standards, multiple reaction monitoring was performed.
he acquired mass transitions are shown in Table 2.
Post-column infusion of neat solutions was used to optimize MS
arameters, mass transitions, and collision energy of the respective
nalytes.
The software TargetLynx (Waters) was used for quantiﬁcation.
he ratio of the peak area of the quantiﬁer (ﬁrst mass transition
f an analyte) to the peak area of the internal standard was cal-
ulated. The qualiﬁer (second mass transition) was used to verify
he retention time of the analytes. In order to improve selectivity
nd detect potential interferences, especially in native samples, we
onitored the ratio of the quantiﬁer and the qualiﬁer. For linearegression, a 1/x2 weighting was used and the origin was excluded.
or smoothing of the peaks, the mean smoothing algorithm with
wo iterations and a smoothing width of three was  employed.292.1 97.0 24 0.016
2.5. Method validation
The  method was validated according to the Guideline of bioana-
lytical method validation by the European Medicines Agency (EMA)
[19].
Five independent sample series were analyzed on different days.
Each series was composed of a blank sample, a zero sample (con-
taining internal standards but no analytes), calibrators, and QC
samples. The calibrators were prepared and analyzed in duplicate
in each series; the QC samples and the LLOQ sample (lower limit
of quantiﬁcation = lowest calibration standard) were prepared and
analyzed 5 times.
The  linearity of the method was  investigated by measuring the
calibration standards for at least 5 different concentration levels.
The correlation coefﬁcient and the slope were calculated.
For  evaluation of within- and between-run imprecision and
accuracy, three levels of QC samples and the LLOQ samples were
examined (n = 5). The variation coefﬁcient (CV), which demon-
strates the imprecision, was calculated for each concentration level
and analyte and should not exceed 15% according to the EMA  guide-
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ine. For the accuracy, the deviation from the nominal value should
ot exceed 15%.
The  LLOQ of corticosterone, cortisone, cortisol, 11-
eoxycortisol, DHEAS, 17-OH-progesterone, progesterone, and
estosterone was deﬁned as a reasonable concentration regarding
ts physiological range or for aldosterone, 11-deoxycorticosterone,
1-deoxycortisol, and DHEA as a concentration that has a signal-
o-noise ratio of at least 5:1 combined with an inaccuracy and
mprecision ≤20 %.
To  investigate potential carry-over, methanol was  injected after
he measurement of the highest calibrator. The methanol sample
as examined for analyte peaks.
Dilution integrity was evaluated by spiking a sample with a con-
entration above the calibration range and dilution of this sample
n two different ways (1:5 and 1:10). The measured concentration
as compared to the expected concentration.
The freeze and thaw stability of the QC samples was  investigated
n 5 freeze and thaw cycles, in which the samples were completely
hawed and refrozen.
To  evaluate the stability of the processed samples, they
emained in the autosampler at 8 ◦C for 24 h and were measured
gain.
We evaluated the matrix effect and the recovery by using a pre-
nd post-spiking experiment according to the procedure given by
atuszewski et al. [20]. In this way, 6 different lots of serum were
ssessed. The serum was collected in Sarstedt tubes (S-Monovette
EF 01.1601). Three aliquots of a serum sample were spiked before
xtraction and 3 aliquots were spiked after extraction. The recovery
as calculated as follows:
ecovery = 100% × cserumpre/cserumpost
To examine the matrix effect, the baseline value of steroids in the
erum lots had to be determined by measuring unspiked aliquots
f each lot (n = 3). These values were subtracted from the measured
alues in the samples spiked after extraction. The peak areas of the
amples spiked after extraction were then compared to the peak
reas of the pure analyte solution in absence of matrix, which was
piked with the same amount of analytes.
atrixeffect = 100% × (cserumpost − cserumbaseline)/csolvent
Additionally, the Guideline of bioanalytical method validation
rom the EMA suggests calculating the IS normalized matrix fac-
or and the variation coefﬁcient of this factor, which should not
e greater than 15%:
atrixfactor(MF) = Areamatrix/Areasolvent
Fnormalized = MFanalyte/MFIS
A post-column infusion experiment was used to further evaluate
he matrix effect. Unspiked matrix was processed and injected on
he column according to the procedure outlined by Bonﬁglio et al.
21]. A solution of all analytes was simultaneously infused into the
ass spectrometer using T-tubing and a syringe pump. The infu-
ion chromatogram of the injected processed matrix was  compared
o an infusion chromatogram of injected methanol. Observation of
ifferences would indicate an inﬂuence of the matrix.
In  each run, the mean of the ion ratios of the calibration stan-
ards were calculated and compared to the mean of the ion ratios
f the serum samples. Deviations in the ion ratios would indicate
nterferences in the sample. The ion ratio in the serum samples
hould not change by 20% from that of the mean ratio of the cal-
bration standards [22]. The variation coefﬁcient was calculated
o monitor alterations of the ratios, which should be very little.
he ratios of different runs were compared. Changes could be an
ndicative for ionization problems.d Biomedical Analysis 142 (2017) 66–73 69
2.6.  Evaluation of sample clean-up
To measure the content of proteins of the processed samples,
and therefore the efﬁcacy of the deproteination step, a Nano-
Drop C2000 (Thermo Scientiﬁc, Waltham, Massachusetts, USA) was
used. To further investigate the purity of the processed samples,
phospholipid proﬁles were assessed with the mass spectrometer
according to the procedure described by Little et al. [23].
3.  Results and discussion
3.1.  Method development
3.1.1.  HPLC–MS/MS method
The  main challenge of the analytical development was the estab-
lishment of a chromatographic method that separates the isobaric
compounds of the panel (corticosterone, 11-deoxycortisol and 21-
deoxycortisol; 17-OH-progesterone and 11-deoxycorticosterone;
and aldosterone and cortisone). Although there are published
methods using C 18 reversed phase columns for similar panels [1],
we could not achieve adequate separation of our targeted isobaric
compounds, i.e., corticosterone and 21-deoxycortisol. Therefore,
the suitability of a biphenyl column (100 mm of length) was  inves-
tigated. In our case, this column improved the chromatographic
resolution, but baseline separation of the isobaric compounds could
only be achieved by using a rather long 150 mm  biphenyl column
(Fig. 2). In addition to the chromatographic separation, the sen-
sitivity was also optimized. For this purpose, we  employed two
different additives of the mobile phase: ammonium formate and
ammonium ﬂuoride in different concentrations. Additionally, two
different ionization techniques, ESI and APCI, were examined for
several analytes. In the end, we decided to use ESI in combination
with 0.2 mM ammonium ﬂuoride as solvent additive.
3.1.2.  Sample preparation
Methanolic  zinc sulfate solutions are widely used as precip-
itation agents for steroids assays [24–26]. We compared this
established reagent with a methanolic ZnTFA solution. In this
regard, a mixture of 80% methanol and 20% aqueous zinc sulfate
(89 g ZnSO4 heptahydrate in 1 L water – equal to 62 mM)  was
compared to a mixture of 80% methanol and 20% aqueous ZnTFA
solution (96 g ZnTFA in 1 L water – equal to 62 mM). According
to the measured protein content (0.6% remaining proteins in the
samples that were precipitated with ZnTFA and 0.7% remaining
proteins in the samples that were precipitated with ZnSO4) the
deproteination efﬁciencies of the two reagents were comparable.
The phospholipid proﬁles of respective processed serum samples
were also similar, and neither a phospholipid carry over nor build
up was observed for either precipitation reagent. Due to the volatil-
ity of TFA in contrast to sulfate, we decided to use ZnTFA as the
precipitation agent to minimize the contamination of the mass
spectrometer.
To further increase the sensitivity of the method, we reduced the
volume of the precipitation agent while simultaneously increasing
the concentration of ZnTFA. Thus, we could create an agent with
the same efﬁcacy, i.e., remaining protein content and phospholipid
proﬁle, but with less dilution of the sample. The ﬁnal precipitation
agent was  composed of 124 mM ZnTFA in pure methanol.
3.2.  Method validationLinearity  could be shown for all analytes over the whole cali-
bration range with a correlation coefﬁcient of R2 > 0.99. The back
calculated concentrations of all calibration standards of the 5 runs
were within ± 15% of the nominal value. The responses of the LLOQs
15
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eig. 2. Chromatograms of all analytes. ALDO: aldosterone, B: corticosterone, 21-
ulfate, DOC: 11-deoxycorticosterone, E: cortisone, F: cortisol, S: 11-deoxycortisol, 
ere at least 5 times the response of the blank sample. Therefore,
he criteria of the EMA  were fulﬁlled.
Evaluation results for accuracy and imprecision (within- and
etween-run) were good for all analytes. All quality controls and
he LLOQs were within the limits of the EMA  guideline (±15% and
20% for the LLOQs, respectively). Table 3 shows the accuracy and
mprecision values of the QCs and LLOQs for all analytes.
Also the certiﬁed controls showed an accuracy and imprecision
f less than 5% for cortisol, 17-OH-progesterone, progesterone and
estosterone (see Table 3).
The carry-over was below the respective LLOQs and therefore
egligible. The dilution integrity could be proven by deviations
rom the calculated values between 0.2% and 11.2% for all analytes
nd both dilution steps.
All  analytes were stable for at least 5 freeze- and thaw cycles, the
eviation ranged from 91.5% to 101%. The deviation of the samples
tored for 24 h in the autosampler was also below the 15% suggested
y the EMA  (87.3%–107%). Therefore, the extracted samples were
etermined to be stable over the runtime of a large batch.
The  results for the recovery were good: 103% cortisol, 94.9%
ortisone, 104% corticosterone, 101% 11-deoxycortisol, 97.5%
7-OH-progesterone, 111% 11-deoxycorticosterone, 101% aldos-
erone, 94.6% progesterone, 96.0% 21-deoxycortisol, 96.2% DHEA,
07% DHEAS and 98.7% testosterone.
Additionally, the observed matrix effect has no relevant inﬂu-
nce on the measurement (99.0% cortisol, 112% cortisone, 93.1%1-deoxycortisol, DHEA: dehydroepiandosterone, DHEAS: dehydoepiandrosterone
P: 17-OH-progesterone, PG: progesterone, T: testosterone.
corticosterone, 100% 11-deoxycortisol, 101% 17-OH-progesterone,
110% 11-deoxycorticosterone, 104% aldosterone, 98.4% proges-
terone, 104% 21-deoxycortisol, 101% DHEA, 97.0% DHEAS and 100%
testosterone). The variation coefﬁcient of the IS normalized matrix
factor ranged from 5.81% to 12.7%, only the value for DHEAS
had a variation coefﬁcient that was  slightly higher than the rec-
ommended 15% (17.1%). The result of the post-column infusion
experiment indicates ion suppression for all analytes of the matrix
samples compared to a solvent injection (see Fig. 3, and Fig. S1 in the
supplementary material in the online version at DOI: http://dx.doi.
org/10.1016/j.jpba.2017.04.020). However, analyzing the results
of  the experiments according to Matuszewski et al., it could be
assumed that the occurring matrix effect can be compensated by
the internal standard, and no relevant matrix effect was  observed.
It  has to be noted that we  could not achieve the required sensi-
tivity for aldosterone and 21-deoxycortisol in healthy individuals.
A modiﬁcation of our LC systems that allowed a post-column infu-
sion of 5% isopropanol to the eluent increased the signals but only
up to 30%, which was  still insufﬁcient for our purpose. A promising
alternative to overcome this obstacle is a more laborious sample
preparation that enables an enrichment of the analyte, e.g., ofﬂine
SPE or LLE [27,28]. However, we also present the chromatographic
results for aldosterone and 21-deoxycortisol to demonstrate the
separation performance of a biphenyl stationary phase.
The  monitored ion ratios showed only little variation. The calcu-
lated within- and between- run CVs of the ratios ranged from 0.14%
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Table  3
Results for accuracy and imprecision.
Analyt LLOQ QC 1 QC 2 QC 3 Certified Controls 
Aldosterone [ng/mL] 0.25  0.30  0.97  29.2  0.44  
Imprecision within-run [%] 8.32 4.04 2.47 4.50 2.44 
Imprecision between-run [%] 8.91 5.28 11.1 6.43 7.66 
Accuracy within-run [%] 102 110 106 110 104 
Accuracy between-run [%] 101 110 108 107 104 
Corticosterone [ng/mL] 0.23  0.33  11.5  68.9  
Imprecision within-run [%] 3.66 1.80 2.67 3.02 
Imprecision between-run [%] 8.39 2.12 4.30 4.04 
Accuracy within-run [%] 103 112 105 101 
Accuracy between-run [%] 102 112 105 101 
Cortisol [ng/mL] 1.08  3.24  80.8  323  101  
Imprecision within-run [%] 3.13 2.08 2.64 4.04 1.70 
Imprecision between-run [%] 9.79 3.53 5.56 5.09 2.59 
Accuracy within-run [%] 97.5 106 106 107 100 
Accuracy between-run [%] 95.6 106 106 107 100 
Cortisone [ng/mL] 1.00  3.00  50.0  200  
Imprecision within-run [%] 3.25 1.99 2.96 5.26 
Imprecision between-run [%] 9.15 2.78 12.0 6.47 
Accuracy within-run [%] 96.9 108 113 111 
Accuracy between-run [%] 95.3 108 113 112 
11-Deoxycorticosterone [ng/mL] 0.02  0.03  1.01  15.1  
Imprecision within-run [%] 5.32 2.95 1.51 3.44 
Imprecision between-run [%] 5.36 5.49 2.34 4.60 
Accuracy within-run [%] 100 115 113 107 
Accuracy between-run [%] 100 109 113 108 
11-Deoxycortisol [ng/mL] 0.12  0.36  5.92  35.5  
Imprecision within-run [%] 3.36 1.75 2.84 3.15 
Imprecision between-run [%] 10.9 2.07 4.78 4.46 
Accuracy within-run [%] 104 113 111 109 
Accuracy between-run [%] 103 113 111 109 
21-Deoxycortisol [ng/mL] 0.19  0.57  9.30  55.8  
Imprecision within-run [%] 6.16 2.97 2.05 4.30 
Imprecision between-run [%] 15.2 5.51 5.63 6.99 
Accuracy within-run [%] 97.9 106 106 102 
Accuracy between-run [%] 96.1 107 106 101 
DHEA [ng/mL] 4.76  14.3  71.3  285  
Imprecision within-run [%] 9.05 2.55 3.01 2.79 
Imprecision between-run [%] 11.6 3.53 4.62 4.40 
Accuracy within-run [%] 103 109 110 109 
Accuracy between-run [%] 103 109 110 110 
DHEAS [ng/mL] 20.1  62.9  525  3147  4660  
Imprecision within-run [%] 6.29 5.43 7.41 7.31 2.32 
Imprecision between-run [%] 9.61 8.50 11.9 9.18 8.36 
Accuracy within-run [%] 98.8 97.3 92.3 96.5 99.9 
Accuracy between-run [%] 97.8 97.7 92.4 99.5 101 
17-OH-Progesterone [ng/mL] 0.08  0.12  1.23  30.8  1.70  
Imprecision within-run [%] 5.52 2.36 2.71 4.17 1.10 
Imprecision between-run [%] 8.48 5.58 4.10 5.15 1.98 
Accuracy within-run [%] 94.1 111 110 109 99.1 
Accuracy between-run [%] 94.1 111 110 112 99.3 
Progesterone [ng/mL] 0.05  0.15  0.98  14.8  3.14  
Imprecision within-run [%] 6.45 2.15 3.16 3.80 0.95 
Imprecision between-run [%] 11.5 3.24 5.54 6.02 2.05 
Accuracy within-run [%] 103 111 112 108 101 
Accuracy between-run [%] 102 112 112 108 101 
Testosterone [ng/mL] 0.02  0.03  1.00  15.1  2.94  
Imprecision within-run [%] 5.39 2.27 2.62 3.67 0.80 
Imprecision between-run [%] 9.20 3.72 4.09 4.22 2.85 
111 
110 
t
d
iAccuracy within-run [%] 99.8 112 
Accuracy between-run [%] 99.8 106 o 6.7%. The deviation between the ratios of the calibration stan-
ards and the ratios of the patient samples was <1.3%. Therefore, no
ndication of an unknown interference in the patient samples was109 104 
110 104 
observed.  A detailed presentation of the ion ratios can be found in
Table S1 in the online version at DOI: http://dx.doi.org/10.1016/j.
jpba.2017.04.020,  in the supplementary material.
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. Conclusion
We  have described a sensitive and selective UHPLC–MS/MS
ethod for identiﬁcation and quantiﬁcation of a large steroid panel.
his method for clinical research is innovative with respect to pre-
ious methods in two essential aspects:
) The novel agent for protein precipitation, i.e., 124 mM zinc
triﬂuoroacetate in methanol enables a good sample clean-up
combined with a low dilution factor of the sample – a critical
point  for low abundant compounds such as 21-deoxycortisol
and 11-deoxycorticosterone.
) Concerning the selectivity of the assay, we could demonstrate
that  biphenyl based stationary phases are a powerful tool for
steroid  assays. Biphenyl groups enable a good separation of
the  isobaric compounds, which are widely occurring in steroid
assays.  Therefore, these stationary phases can be tested as an
alternative  in cases in which C 18 columns do not lead to the
required  separation. In combination with an elaborate sample
preparation that enables an enrichment of analytes, the result-
ing  selectivity may  facilitate the assessment of new, expanded
steroid  proﬁles including highly related parameters such as cor-
ticosterone, 11- and 21-deoxycortisol.
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Figure S1 Exemplarily chromatograms of 6 analytes of the post column infusion experiment using specific 
transitions. The upper line displays the infusion chromatogram of injected methanol; the lower line displays the 
injected processed matrix. The peak represents the retention time of the respective analyte. 
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Table S1 Ion ratios of the calibration standards (CAL) and the serum samples. 
 
 
  Run 1 Run 2 Run 3 Run 4 Run 5 
    CAL samples  CAL samples  CAL samples  CAL samples  CAL samples  
Cortisol Mean 2.534 2.513 2.524 2.510 2.529 2.541 2.549 2.536 2.583 2.581 
 
Min 2.51 2.475 2.481 2.464 2.335 2.485 2.444 2.5070 2.536 2.505 
 
Max 2.564 2.562 2.564 2.529 2.680 2.672 2.676 2.578 2.646 2.726 
  CV [%] 0.8171 1.154 1.267 0.8843 3.102 2.317 2.172 0.9910 1.683 2.064 
Cortisone Mean 4.461 4.451 4.460 4.424 4.440 4.587 4.514 4.512 4.492 4.517 
 
Min  4.402 4.388 4.347 4.282 4.004 4.451 4.452 4.304 4.322 4.442 
 
Max 4.513 4.522 4.537 4.487 4.639 4.799 4.733 4.758 4.794 4.650 
  CV [%] 0.9292 1.287 1.212 1.668 3.361 2.948 1.787 3.505 2.763 1.380 
Corticosterone Mean 2.594 2.582 2.567 2.575 2.594 2.622 2.650 2.632 2.608 2.622 
 
Min  2.511 2.505 2.490 2.445 2.479 2.556 2.490 2.612 2.558 2.503 
 
Max 2.668 2.638 2.643 2.628 2.650 2.689 2.890 2.644 2.659 2.750 
  CV [%] 2.689 1.544 1.929 2.099 1.990 1.504 3.285 0.491 0.994 2.072 
11-Deoxycortisol Mean 2.077 2.053 2.092 2.057 2.088 2.058 2.098 2.087 2.088 2.077 
 
Min  2.007 1.971 1.826 1.975 2.018 2.007 2.051 2.073 2.04 2.031 
 
Max 2.109 2.074 2.169 2.084 2.124 2.140 2.257 2.138 2.159 2.102 
  CV [%] 1.651 1.649 3.870 1.756 1.245 2.007 2.298 1.199 1.311 0.9003 
17-OH-Progesterone Mean 2.178 2.134 2.156 2.180 2.172 2.112 2.143 2.172 2.161 2.174 
 
Min  2.11 2.065 2.04 2.176 2.046 2.038 2.020 2.150 2.080 2.078 
 
Max 2.233 2.230 2.184 2.185 2.280 2.189 2.192 2.194 2.221 2.339 
  CV [%] 1.623 2.514 1.671 0.1384 2.222 2.07 2.392 0.988 1.643 2.701 
Deoxycorticosterone Mean 2.234 2.228 2.218 2.213 2.227 2.205 2.234 2.218 2.251 2.239 
 
Min  2.195 2.204 2.110 2.179 2.172 2.172 2.186 2.167 2.128 2.187 
 
Max 2.274 2.249 2.266 2.248 2.257 2.274 2.294 2.241 2.381 2.258 
  CV [%] 1.159 0.755 1.906 0.978 1.165 1.527 1.184 1.293 2.514 0.798 
Progesterone Mean 0.8578 0.8577 0.8603 0.8573 0.8691 0.8512 0.8622 0.8542 0.8577 0.8589 
 
Min  0.832 0.854 0.831 0.839 0.827 0.844 0.839 0.839 0.822 0.852 
 
Max 0.854 0.861 0.945 0.867 0.974 0.863 0.911 0.865 0.931 0.864 
  CV [%] 2.095 0.3352 3.936 1.271 5.588 0.8052 2.636 1.300 3.449 0.5528 
21-Deoxycortisol Mean 1.511 1.524 1.538 1.530 1.557 1.533 1.564 1.533 1.554 1.511 
 
Min  1.491 1.504 1.506 1.517 1.526 1.506 1.531 1.519 1.533 1.467 
 
Max 1.529 1.534 1.620 1.540 1.581 1.555 1.608 1.567 1.573 1.530 
  CV [%] 0.7794 0.7306 2.081 0.491 0.8996 1.540 1.288 1.208 0.8825 1.191 
DHEA Mean 0.3633 0.3575 0.3586 0.3578 0.3684 0.3628 0.3661 0.3695 0.3699 0.3719 
 
Min  0.356 0.349 0.345 0.352 0.354 0.354 0.347 0.363 0.361 0.361 
 
Max 0.387 0.362 0.395 0.364 0.429 0.370 0.379 0.375 0.375 0.38 
  CV [%] 3.236 1.333 5.261 1.440 6.067 1.904 2.954 1.052 1.263 1.611 
Testosterone Mean 0.7564 0.7506 0.7566 0.7643 0.7585 0.7387 0.7541 0.7638 0.7618 0.7617 
 
Min 0.748 0.744 0.739 0.748 0.75 0.692 0.722 0.757 0.743 0.745 
 
Max 0.777 0.766 0.774 0.775 0.777 0.757 0.774 0.770 0.778 0.778 
 
CV [%] 1.166 0.9392 1.218 1.108 0.9160 2.957 2.020 0.5661 1.194 1.064 
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a  b  s  t  r  a  c  t
Background:  Stimulation  with  intravenous  adrenocorticotropic  hormone  (ACTH)  is  a widely  used  diagnos-
tic  procedure  to characterize  the  adrenocortical  function.  Currently,  the  response  of serum  cortisol,  mainly
quantiﬁed  by immunoassays,  is  the  only  established  read-out  of  this  test. By  using  liquid chromatogra-
phy  coupled  with  mass  spectrometry  (LC–MS/MS)  simultaneous  determination  of  several  steroids  that
respond  to ACTH  stimulation  is  now  possible.  The  aim  of  this  study  was  to further  characterize  the  typical
effect  of  exogenous  ACTH  (250  mg)  on a LC–MS/MS-serum  steroid  proﬁle.
Methods:  A  set of 36 paired  samples  (pre-/post-IV-ACTH)  was  investigated  (age range  22–58,  26 female
and  10  male  individuals).  Serum  steroid  proﬁling  was  performed  using  a LC–MS/MS  method  covering
cortisol,  cortisone,  corticosterone,  11-deoxycortisol,  17-OH-progesterone  and  11-deoxycorticosterone.
Results: The  concentrations  of  all measured  steroids  increased  after  stimulation  with  ACTH,  except  for
cortisone.  Serum  corticosterone,  11-deoxycorticosterone  and  11-deoxycortisol  showed  markedly  moreorticosterone pronounced  relative  increases  compared  to  cortisol.  The  strongest  response  was  observed  for  corticos-
terone  (15-fold  median  relative  increase,  compared  to 1.4-fold  median  increase  of  cortisol).
Conclusion: Serum  steroid  proﬁling  using  LC–MS/MS  after  stimulation  with  IV  ACTH  demonstrates  highly
dynamic  response  patterns.  Further  studies  should  address  in particular  serum  corticosterone  as  a poten-
tial  novel  marker  of  biochemical  stress  response.. Introduction
The assessment of panels of analytes which are related to a
etabolic pathway, referred to as metabolic proﬁling [1], is promis-
ng for clinical diagnostics. The simultaneous quantiﬁcation of
arious endogenous steroids has already become a valuable diag-
ostic tool in some areas of endocrinology [2] and beyond. The
iosynthesis pathway of these steroids is shown in Fig. 1. So far,
teroid proﬁling is used to conﬁrm congenital adrenal hyperplasia
3], to investigate primary aldosteronism [4] and in the diagnostic
ork-up of other forms of adrenal cortical dysfunction [5,6]. More-
ver, in endocrinological oncology, steroid proﬁling has become
ncreasingly attractive as a tool for differential diagnosis, as demon-
trated in recent work on adrenal tumours by Arlt et al. [7].
∗ Corresponding author at: Johanna Lindner, Institute of Laboratory Medicine,
ospital  of the University of Munich (LMU), Marchioninistrasse 15, 81377 Munich,
ermany.
E-mail address: johanna.lindner@med.uni-muenchen.de (J.M. Lindner).
1 Both authors contributed equally to this work.
ttps://doi.org/10.1016/j.jpba.2017.12.045
731-7085/© 2018 Elsevier B.V. All rights reserved.©  2018  Elsevier  B.V.  All  rights  reserved.
Stimulation testing with IV adrenocorticotropic hormone
(ACTH) is a long-established approach to characterize the func-
tional integrity of the adrenal cortex. Standard read-out of this
test is the concentration of total cortisol in serum samples 60 min
after ACTH administration. An increase of serum cortisol >18 g/dL
is considered normal [8]. ACTH stimulation testing is used in
suspected adrenal failure due to different potential underlying con-
ditions, including relative adrenal insufﬁciency in septicemia and
septic shock [9].
Cortisol  as the single read-out of the ACTH stimulation test
is usually quantiﬁed by immunoassays. However, particularly in
some clinical conditions such as sepsis [9], immunoassays can lead
to inaccurate results due to cross reactivity with structurally simi-
lar analytes [10,11]. Serum steroid proﬁling using isotope dilution
liquid chromatography mass spectrometry (ID-LC–MS/MS) enables
the researcher to monitor several steroids simultaneously on a very
high level of analytical speciﬁcity as well as accuracy − even for
structurally closely related compounds. Therefore it is becoming
the method of choice to quantify steroids in diagnostic samples
[12,13].
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Additionally, IV ACTH stimulation simulates maximum physi-
logical stress and allows studying biochemical stress responses
n different biological levels. Steroid proﬁling of ACTH stimu-
ated samples by LC–MS/MS represents a far more comprehensive
pproach to describe the biochemical response of the adrenal
ortex to ACTH compared to mere immunometric cortisol mea-
urement.
So far, there are solely data published on corticosteroid proﬁles
fter ACTH stimulation for cases of adrenocortical adenomas [14]
nd adrenal insufﬁciency [15], but there are only sparse data for
ontrol cohorts and healthy individuals [15].
Comparative and comprehensive data of steroid proﬁling in
eﬁned cohorts after ACTH administration are needed to study
ifferences in the physiological reactions to stress. Therefore the
im of our investigation was to assess the characteristic pat-
ern of changes in concentration of 6 steroids (cortisol, cortisone,
orticosterone, 11-deoxycortisol, 11-deoxycorticosterone and 17-
H-progesterone) in human serum of individuals not suspected to
e suffering from endocrinological diseases which can be reliably
uantiﬁed using a recently developed ID-LC–MS/MS method for
linical research [16].
.  Materials and methods
.1.  Sample collectionSamples  of 36 individuals were investigated. Of these, 24 paired
amples (pre-/post-IV-ACTH) were residual, anonymized clini-
al samples from women attending a fertility outpatient service. of corticosteroids.
Only  samples were included if the increase in serum cortisol
after ACTH administration was normal and above the cut-off
(>18 g/dL [8], measured by enzyme immunoassay), and if all
requested routine laboratory tests did not show any abnormal-
ities. Adrenal hyperplasia was excluded by the evaluation of
serum 17-OH-progesterone values after ACTH stimulation mea-
sured by LC–MS/MS (<1 g/dL, [17]). Testosterone was  measured
by an immunoassay and all values were ≤0.06 g/dL for these
females. The other 12 paired samples (10 male, 2 female, age
26–58 years) were obtained from volunteers after informed con-
sent. These volunteers were free of health complaints (including
sleep disorders) or evidence of diseases, were not overweight
(BMI < 25) and didn’t take steroid medication except contracep-
tives. The study protocol was  approved by the institutional review
board of the Ludwig-Maximilians-Universität Munich, Germany
(No 84/15). ACTH stimulation was  performed in all individuals by
an intravenous injection of tetracosactidhexaacetat (250 micro-
grams = 25 I.E., Synacthen
®
, sigma-tau GmbH, Munich, Germany).
Blood samples were taken in the non-fasting state in the morn-
ing (9–11 a.m.) prior to ACTH administration and 60 min after
stimulation. In the sub-set of 12 volunteers serum sampling
was also performed 30 min  after stimulation. Blood samples
were left to clot for 15 min  and subsequently centrifuged. The
obtained serum was anonymized and stored at −80 ◦C until anal-
ysis. Mean age of the entire cohort investigated in this study
(n = 36) was 31 (range 22–58), 26 female (all pre-menopausal), 10
male.
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Table  1
Serum steroid concentrations observed before and after ACTH administration in complete cohort [10 male, 26 female; g/L].
time mean median range relative increase [x-fold]
median range
Cortisol 0  min  111 106 32.4–213 – –
60 min  267 261 181–407 1.40 0.300–4.58
Cortisone 0  min  19.9 19.9 11.2–29.4 – –
60 min 18.1 18.3 11.4–23.4 −0.084 −0.442 to 0.518
Corticosterone 0  min  2.68 1.81 0.684–9.20 – –
60 min  31.3 31.0 17.3–47.7 15.2 2.12–58.7
11-Deoxycortisol 0  min  0.243 0.229 <0.110–0.772 – –
60 min  0.897 0.822 0.241–4.37 2.75 0.181–10.8
11-Deoxy-
corticosterone
0  min  0.048 0.027 <0.022–0.232 – –
60 min 0.235 0.190 0.037–1.15 5.72 1.45–15.4
68 <0.070–2.42 – –
27 0.442–3.04 1.98 −0.257 to 9.06
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Fig. 2. Relative increase (x-fold) of steroids in serum after iv ACTH administration
(250  g) (0 min  to 60 min). The bars display the minimum and the maximum of the17-OH-Progesterone 0  min  0.648 0.4
60 min  1.47 1.
.2. LC–MS/MS assay
Steroid  proﬁling of the serum samples was performed using a
alidated, semi-automated stable-isotope dilution-UHPLC–MS/MS
ssay as previously described in detail [16]. Isobaric compounds
ere chromatographically separated. For detection a Xevo TQ-S
Waters, Milford, MA,  USA) was used and multiple reaction moni-
oring (MRM)  was applied.
For quality assurance, a matrix-based quality control,
Lyphochek
®
Immunoassay Plus Control, Level 2” (Biorad, Munich,
ermany) was used together with in-house prepared quality con-
rol samples. The exact concentrations of calibrators and quality
ontrols are listed in the supplementary material (Table S1).
.  Results
The basal steroid levels, the concentrations after ACTH adminis-
ration, and the x-fold relative increase (c60min − c0min)/c0min of the
teroids are given in Table 1. Marked increase in the concentration
f all analytes except cortisone − the inactivated storage form of
ortisol − was observed.
The  most pronounced dynamics after ACTH administration were
ound for corticosterone, which showed a relative median 15.2-fold
ncrease. Corticosterone also displayed the highest inter-individual
ariance, as illustrated in Fig. 2.
We differentiated these data between women and men  to detect
ossible sex-speciﬁc differences in the adrenal secretion. Indeed,
7-OH-progesterone displays differing values between sexes: the
edian value for male individuals (1.72 g/L) was  higher com-
ared to female individuals (1.12 g/L), ACTH administration led
o a clearly more pronounced increase in women (2.6-fold versus
.9-fold) (see Table 2).
In  the sub-set of volunteers (n = 12), serum sampling was  per-
ormed after 60 min  and additionally also after 30 min  of ACTH
dministration. Thus, we were able to investigate the time course of
he corticosteroid concentrations. We  found that the main increase
f the corticosteroids occurred within the ﬁrst 30 min after ACTH
timulation. Sixty minutes after stimulation, the results were only
lightly higher than or equal to the 30 min  values (see Table 3).
. Discussion
In this article, we report the application of a multi-analyte, sta-
le isotope-dilution LC–MS/MS method for serum steroid proﬁling
fter stimulation with IV ACTH. Our main ﬁnding is that several
teroids (11-deoxycorticosterone, 11-deoxycortisol, and corticos-
erone in particular) displayed a far more pronounced dynamicrespective increases. The different number of cases results from the lacking basal
concentration of some samples due to their low concentrations (<LLOQ).
response to ACTH administration compared to cortisol, currently
the only standard read-out of the ACTH stimulation testing. Most
pronounced increase was observed for corticosterone (15-fold rel-
ative increase in relation to a 1.4-fold relative increase of cortisol,
both expressed as median). This suggests this analyte as a novel
and probably very sensitive marker in research addressing stress
and the body’s biochemical response to maintain haemostasis.
Regarding the ACTH stimulation test in clinical diagnostic situa-
tions, abovementioned precursors as well as combinations of these
might be a more powerful readout than cortisol alone; respective
future studies to establish reference ranges and to test this hypoth-
esis seem justiﬁed.
To  the best of our knowledge, the steroid proﬁle described
in our work has not been investigated in the context of ACTH
stimulation so far. In general there are very few data on steroid
proﬁling in individuals without endocrine disorders after ACTH
stimulation. However, we were able to compare our data with the
results of Holst et al. who assessed steroid data of patients with
adrenal insufﬁciency and also of healthy individuals after ACTH
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Table  2
Serum steroid concentrations observed before and after ACTH administration, data separated in women (n = 26) and men  (n = 10) [g/L].
relative increase [x-fold]
time mean median range median range
women men  women  men  women  men  women men  women men
Cortisol 0 min  106 127 92.6 124 32.4–213 68.2–203 – – – –
60 min  272 261 267 260 181–407 236–302 1.73 1.24 0.668–4.58 0.300–2.70
Cortisone 0 min  20.0 19.5 17.7 18.3 11.2–29.4 15.4–25.6 – – – –
60 min 20.8  19.2 17.8 19.5 11.4–23.4 14.2–23.1 −0.155 0.016 −0.442 to 0.518 −0.374 to 0.247
Corticosterone 0  min 2.37  3.50 1.77 2.20 0.684–8.08 0.987–9.20 – – – –
60 min  31.4 30.9 32.4 29.3 17.3–46.8 21.5–47.7 17.0 13.7 3.26–58.7 2.12–28.1
11-Deoxycortisol 0 min  0.210 0.323 0.181 0.266 0.108–0.374 0.222–0.772 – – – –
60 min  0.894 0.906 0.758 0.924 0.241–4.37 0.323–1.70 3.39 2.65 0.181–10.8 1.07–3.78
11-Deoxy-
corticosterone
0 min  0.041 0.059 0.034 0.025 0.022–0.088 0.021–0.232 – – – –
60 min  0.228 0.254 0.191 0.180 0.037–1.15 0.088–0.972 6.08 5.34 1.45–15.4 3.19–11.4
17-OH-Progesterone 0 min  0.481 1.08 0.305 1.08 0.058–2.42 0.485–1.968 – – – –
60 min  1.27 2.00 1.12 1.72 0.442–2.92 1.22–3.04 2.56 0.857 −0.257 to 9.06 0.152–2.61
Table 3
Serum steroid concentrations [g/L] of a sub-cohort (n = 12). Sampling was performed before, 30 min  and 60 min  after ACTH administration.
time mean median range relative  increase [x-fold]
median range
Cortisol 0 min  134 124 68.2–213 – –
30  min  253 246 216–361 0.95 0.263–2.54
60  min 272 260 236–407 1.12 0.300–2.70
Cortisone 0  min  19.2 18.1 15.4–25.6 – –
30  min  17.6 17.9 13.8–19.6 −0.04 −0.392 to 0.089
60  min  19.3 19.5 14.2–23.1 0.035 −0.374 to 0.247
Corticosterone 0  min  3.24 2.10 0.987–9.20 – –
30  min 26.2 25.4 16.9–48.1 10.5 1.69–23.9
60  min  30.3 28.9 21.5–47.7 13.3 2.12–28.1
11-Deoxycortisol 0  min  0.323 0.266 <0.110–0.772 – –
30  min  0.799 0.843 0.263–1.72 2.18 0.401–3.58
60  min  0.874 0.920 0.323–1.70 2.65 1.07–3.78
11-Deoxy-
corticosterone
0  min  0.066 0.025 <0.022–0.232 – –
30  min  0.205 0.146 0.062–0.911 6.60 1.30–8.09
60  min 0.231 0.157 0.088–0.972 5.72 3.19–11.4
.963 0.058–1.97 – –
1.83 0.544–3.09 0.97 0.186–13.7
1.67 0.592–3.04 0.94 0.152–16.1
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Table 4
Comparison with literature data [15] for corticosteroid proﬁling of healthy individ-
uals [g/L, expressed as mean].
Holst et al., 2007 Own data
complete cohort sub-cohort
Sex 38 female, 23 male 26 female, 10 male 2 female, 10 male
Age 24–61 22–58 26–58
n  61 36 12
Cortisol
basal 115 111 134
30  min  266 nd 253
60  min  311 267 272
11-Deoxycortisol
basal  0.79 0.243 0.323
30 min  5.71 nd 0.799
60 min  6.70 0.897 0.874
17-OH-Progesterone
basal  0.47 0.648 0.916
30 min  1.50 nd 1.8017-OH-Progesterone 0  min  0.916 0
30  min  1.80 
60  min  1.80 
dministration [15]. The proﬁle described by Holst et al. (cortisol,
1-deoxycortisol, 17-OH-progesterone, progesterone, androstene-
ione, dehydroepiandrosterone, dehydroepiandrosterone-sulfate,
stradiol,  testosterone and aldosterone) overlaps partially our
roﬁle, i.e. regarding cortisol, 11-deoxycortisol and 17-OH-
rogesterone. While the values and relative increases for cortisol
nd 17-OH-progesterone agreed quite well with the results of
ur work (see Table 4), a striking difference was observed for
1-deoxycortisol: Holst et al. describe substantially higher concen-
rations of this analyte, both pre- and post ACTH administration.
his might be explained by co-elution of 11-deoxycortisol together
ith its isomere corticosterone in one of the LC–MS/MS method
pplied by Holst et al.; notably the authors give no detailed infor-
ation of speciﬁcity in the detection of these two  compounds in
ne of their employed LC–MS/MS methods. This observation under-
ines the crucial importance of proper chromatographic separation
f isobaric compounds in quantitative analysis using LC-MS/MS, in
articular in steroid testing.In  further studies, only baseline values for healthy volunteers
ere available for comparison: Di Dalmazi et al. [14] assessed
he steroid proﬁle of patients with different disorders after ACTH
dministration by LC–MS/MS. In the respective healthy control
60 min  1.62 1.47 1.80
nd, not determined.
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[19]  V.M. Carvalho, O.H. Nakamura, J.G. Vieira, Simultaneous quantitation of seven
endogenous C-21 adrenal steroids by liquid chromatography tandem mass
spectrometry in human serum. Journal of Chromatography B, Anal. Technol.
Biomed. Life Sci. 872 (2008) 154–161.J.M. Lindner et al. / Journal of Pharmaceutic
roup, only the basal levels were determined. Other studies
ddressing steroid proﬁling, e.g. those by Fanelli et al. [18] or Car-
alho et al. [19] did not perform ACTH stimulation. A comparison
f these published baseline values with our data can be found in
he supplementary material (Table S2, S3 and S4). Whereas for
ome values good agreement was found, e.g. between the baseline
anges of serum steroids established by Carvalho et al. [19] and
ur results (see supplementary material Table S2) and the base-
ine cortisol values obtained by Di Dalmazi (see supplementary
aterial Table S3), there are also several discrepancies: The base-
ine concentrations of cortisol, corticosterone, 11-deoxycortisol
nd 17-OH-progesterone of the pre-menopausal women  measured
y Fanelli et al. [18] are higher than the concentrations observed
n the pre-menopausal women in our study (see supplementary
aterial Table S4). Compared to the data of Di Dalmazi [14] the
oncentration of 17-OH-progesterone is lower than the concentra-
ion measured by us whilst the concentrations of corticosterone,
1-deoxycorticosterone, and 11-deoxycortisol are higher than our
alues. These discrepancies raise the question if inter-individual
iological ranges of steroids are indeed very wide or if the different
esults might originate from differences in quantiﬁcation and stan-
ardization of methods. Thus, it seems to be important to perform
ethod comparisons between different laboratories addressing
teroid proﬁling by LC-MS/MS in order to achieve standardization
f steroid proﬁling after ACTH challenge.
Our data presented herein demonstrate the feasibility of com-
lex serum steroid proﬁling in the context of ACTH stimulation
esting using a highly speciﬁc and carefully evaluated isotope
ilution-LC–MS/MS assay. However, a limitation of our investiga-
ion is the incomplete characterization and the heterogeneity of the
et of study samples. While the number of self-reporting healthy
olunteers is rather small, little information was  available concern-
ng the left-over clinical samples. They originated from younger
omen addressing a fertility outpatient clinic; this fact and unre-
arkable results of standard laboratory tests make the presence of
evere diseases in these individuals unlikely. Thus, our data display
ypical results but don’t meet the criteria of reference ranges. The
omposition of the cohorts studied herein only allows qualitative
nterpretation − this is in particular the more dynamic response of
everal corticosteroids (and in particular of corticosterone) com-
ared to cortisol. Deﬁnite sex and age-speciﬁc reference ranges
or application in diagnostic studies remain to be established in
ell-characterized cohorts under highly standardized conditions
including fasting status, comprehensive data about general health
nd detailed endocrinological assessment).
In summary we conclude that isotope dilution-LC–MS/MS-
ased  corticosteroid proﬁling after application of exogenous ACTH
ffers a promising and convenient tool for a far more detailed
ssessment of the adrenal function compared to the mere quantiﬁ-
ation of serum cortisol. This analytical approach may  be relevant
or diagnostic testing as well as for stress research and clinical
esearch on suspected relative adrenal failure, including adrenal
ysfunction associated with severe illness. In particular the eval-
ation of serum corticosterone concentrations as novel highly
ynamic and potentially very sensitive biochemical stress marker
eems worthwhile according to our data.
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Table S1 Concentrations (µg/L) of calibrators and controls  
 
cortisol cortisone 
cortico-
sterone 
11-deoxy-
cortisol 
11-deoxy-
corticosterone 
17-OH-
progesterone 
Cal 1 1.11 1.11 0.228 0.110 0.022 0.066 
Cal 2 5.57 2.77 0.569 0.220 0.054 0.133 
Cal 3 27.8 5.54 1.14 0.550 0.109 0.265 
Cal 4 55.7 11.1 2.85 1.10 0.218 0.664 
Cal 5 111 27.7 8.54 2.75 1.09 1.33 
Cal 6 278 55.4 22.8 8.25 5.44 6.64 
Cal 7 557 111 56.9 22.0 21.8 26.5 
       
QC low 3.34 3.33 0.683 0.330 0.065 0.199 
QC medium 77.9 22.2 5.69 1.65 0.544 0.929 
QC high 334 66.5 22.8 11.0 10.9 13.3 
Lyphocheck 2 198 8.50 1.54 0.29 - 1.83 
Cal, calibrator 
QC, quality control 
 
 
 
Table S2 Comparison with literature data of baseline corticosteroid profiling of individuals without endocrine 
disorders (expressed as ranges in µg/L) 
 Carvalho et al., 2008 [19]  Own data 
     
Sex    female and male 26 female, 10 male 
Age 18-67 22 - 58 
n see below 36 
    
 
[nmol/L] converted to 
[µg/L] 
[µg/L] 
cortisol  176.6 - 714.6 (n = 58) 64.0 - 259  32.4 - 213 
cortisone 22.1 - 97.1 (n = 58) 7.97 - 35.0  11.2 - 29.4 
corticosterone ≤ 67.4 (n = 58) ≤ 23.4  0.684 - 9.20 
11-deoxycortisol  ≤ 2.3 (n = 138) ≤ 0.797 < 0.110 - 0.772 
11-deoxycorticosterone  ≤ 0.7 (n = 138) ≤ 0.231  < 0.022 - 0.232 
17-OH-progesterone  ≤ 5.1 (n = 53, only male) ≤ 1.69  < 0.485 - 1.97 (n = 10, only male) 
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Table S3 Comparison with literature data of baseline corticosteroid profiling of individuals without endocrine 
disorders (expressed as mean in µg/L) 
 
 
 
 
Table S4 Comparison with literature data of baseline corticosteroid profiling of individuals without endocrine 
disorders (expressed as median in µg/L) 
 Fanelli et al., 2011 [18] Own data 
   
Sex women women  
 pre-menopausal pre-menopausal 
Age 18-54 22-34 
n 134 26 
   
cortisol  102 92.6 
corticosterone  2.62 1.77 
11-deoxycortisol  0.239 0.181 
17-OH-progesterone  0.578 0.305 
 
 
 Di Dalmazi et al., 2015 [14]  Own data 
   
Sex 128 female, 60 male  26 female, 10 male 
Age Mean = 61.1  22-58 (mean = 31) 
n 188  36 
    
cortisol  116  111 
corticosterone 3.18  2.68 
11-deoxycortisol  0.34  0.243 
11-deoxycorticosterone  0.080  0.048 
17-OH-progesterone  0.450  0.648 
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3. Appendix 
3.1. List of abbreviations 
ACTH  adrenocorticotropic hormone 
CRH  corticotropin releasing hormone 
LC  liquid chromatography 
MS  mass spectrometry 
TFA  trifluoroacetate 
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